Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trials A-flutter

This article was originally published in The Gray Sheet

Executive Summary

FDA issues 1guidance Aug. 5 on how to design clinical studies for atrial flutter ablation. Early PMA applications for catheter ablation systems to treat atrial flutter relied on single-arm trials, but FDA recommends future submissions use randomized, controlled trials. The agency will consider alternative designs, but the burden of proof will be greater in those instances. The primary effectiveness endpoint should be chronic success, defined as the absence of recurrent atrial flutter after six months, or a surrogate endpoint of acute procedural success in appropriate cases. The primary safety endpoint should be a composite of serious adverse events after seven days
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT026449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel